CIPN is nerve damage caused by the very cancer treatments meant to save lives.
Current treatments can relieve pain, but their risks can limit long-term use.
Weight loss with today’s therapies can come at the expense of lean mass.
MIRA develops novel oral drug candidates designed to build on validated biological targets while addressing limitations of existing therapies.
Our Pipeline
Loading latest news...
